Top-Rated Stocks NASDAQ:VRDN Viridian Therapeutics - VRDN Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Viridian Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $37.30 +0.78 (+2.14%) (As of 02/1/2023 12:00 AM ET) Add Compare Share Share Today's Range$36.41▼$37.6550-Day Range$22.61▼$37.6052-Week Range$9.47▼$39.00Volume401,924 shsAverage Volume652,880 shsMarket Capitalization$1.06 billionP/E RatioN/ADividend YieldN/APrice Target$44.60 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Viridian Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside19.6% Upside$44.60 Price TargetShort InterestHealthy8.61% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.86Based on 7 Articles This WeekInsider TradingSelling Shares$3.68 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.55) to ($3.33) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.20 out of 5 starsMedical Sector503rd out of 1,053 stocksMedical Laboratories Industry16th out of 25 stocks 3.5 Analyst's Opinion Consensus RatingViridian Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $44.60, Viridian Therapeutics has a forecasted upside of 19.6% from its current price of $37.30.Amount of Analyst CoverageViridian Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 4.0 Short Interest Percentage of Shares Shorted8.61% of the outstanding shares of Viridian Therapeutics have been sold short.Short Interest Ratio / Days to CoverViridian Therapeutics has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Viridian Therapeutics has recently decreased by 11.23%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldViridian Therapeutics does not currently pay a dividend.Dividend GrowthViridian Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VRDN. Previous Next 3.3 News and Social Media Coverage News SentimentViridian Therapeutics has a news sentiment score of 0.86. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Viridian Therapeutics this week, compared to 2 articles on an average week.Search Interest7 people have searched for VRDN on MarketBeat in the last 30 days. This is an increase of 75% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Viridian Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Viridian Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,684,652.00 in company stock.Percentage Held by InsidersOnly 4.48% of the stock of Viridian Therapeutics is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Viridian Therapeutics are expected to grow in the coming year, from ($3.55) to ($3.33) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Viridian Therapeutics is -8.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Viridian Therapeutics is -8.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioViridian Therapeutics has a P/B Ratio of 15.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Viridian Therapeutics (NASDAQ:VRDN) StockViridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include Cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma, and Remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.Read More Receive VRDN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Viridian Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address VRDN Stock News HeadlinesJanuary 31, 2023 | americanbankingnews.comJefferies Financial Group Comments on Viridian Therapeutics, Inc.'s FY2025 Earnings (NASDAQ:VRDN)January 27, 2023 | ca.finance.yahoo.comViridian Therapeutics (NASDAQ:VRDN) delivers shareholders solid 105% return over 1 year, surging 4.6% in the last week aloneFebruary 2, 2023 | Tradewins (Ad)Know Your Profit Potential BEFORE You Trade!I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! January 27, 2023 | americanbankingnews.comLara Meisner Sells 6,843 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) StockJanuary 25, 2023 | seekingalpha.comWhy Viridian Therapeutics Is One Of My 2023 Top PicksJanuary 11, 2023 | marketwatch.comViridian Therapeutics Shares Rise 16% After Positive Trial Data for VRDN-001 Eye TreatmentJanuary 9, 2023 | markets.businessinsider.comViridian Announces Positive Data From Phase 1/2 Trial Of Low Dose VRDN-001 In Thyroid Eye DiseaseJanuary 9, 2023 | markets.businessinsider.comViridian Therapeutics Stock Gains 17%February 2, 2023 | Tradewins (Ad)Know Your Profit Potential BEFORE You Trade!I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! January 9, 2023 | msn.comViridian adds 16% after low dose data for thyroid eye disease candidateJanuary 8, 2023 | finance.yahoo.comViridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating Low Dose VRDN-001 in Patients with Thyroid Eye Disease (TED)January 3, 2023 | finance.yahoo.comViridian Therapeutics to Webcast Presentation at the 41st Annual J.P. Morgan Healthcare ConferenceDecember 21, 2022 | technews.tmcnet.comViridian Therapeutics Announces First Patient Enrolled in the 'THRIVE' Phase 3 Trial in Patients With Thyroid Eye DiseaseDecember 21, 2022 | finance.yahoo.comViridian Therapeutics Announces First Patient Enrolled in the ‘THRIVE’ Phase 3 Trial in Patients With Thyroid Eye DiseaseDecember 15, 2022 | seekingalpha.comViridian: Better Data Than A Blockbuster CompetitorNovember 28, 2022 | finance.yahoo.comViridian Therapeutics To Participate In The Evercore ISI HealthCONx ConferenceNovember 17, 2022 | finance.yahoo.comWall Street Analysts Predict an 89% Upside in Viridian Therapeutics, Inc. (VRDN): Here's What You Should KnowNovember 16, 2022 | finance.yahoo.comViridian Therapeutics Third Quarter 2022 Earnings: Beats ExpectationsNovember 14, 2022 | finance.yahoo.comAt Higher Dose, Viridian's Thyroid Eye Disease Candidate Shows Significant, Rapid Improvement In Signs & SymptomsNovember 14, 2022 | seekingalpha.comViridian Therapeutics, Inc. (VRDN) Q3 2022 Earnings Call TranscriptNovember 14, 2022 | finance.yahoo.comViridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Tops Revenue EstimatesNovember 14, 2022 | finance.yahoo.comViridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED)November 14, 2022 | finance.yahoo.comViridian Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate UpdatesNovember 8, 2022 | finance.yahoo.comViridian Therapeutics to Report Third Quarter 2022 Financial Results and Host Conference Call on November 14, 2022November 8, 2022 | finance.yahoo.comViridian Therapeutics to Participate in Guggenheim 4th Annual Neuro/Immunology Conference on November 15thOctober 22, 2022 | finance.yahoo.comViridian Presents Positive Clinical Data from Ongoing VRDN-001 Phase 1/2 Trial in Active Thyroid Eye Disease (TED) Patients During Late-Breaking Presentations at the American Thyroid Association (ATA) 91st Annual MeetingOctober 12, 2022 | finance.yahoo.comViridian Therapeutics, Inc.'s (NASDAQ:VRDN) Intrinsic Value Is Potentially 97% Above Its Share PriceSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive VRDN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Viridian Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address VRDN Company Calendar Last Earnings11/14/2022Today2/02/2023Next Earnings (Estimated)3/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VRDN CUSIPN/A CIK1590750 Webwww.viridiantherapeutics.com Phone(617) 272-4600Fax760-537-4101Employees50Year FoundedN/APrice Target and Rating Average Stock Price Forecast$44.60 High Stock Price Forecast$51.00 Low Stock Price Forecast$35.00 Forecasted Upside/Downside+19.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($4.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-79,410,000.00 Net Margins-6,009.30% Pretax Margin-6,009.30% Return on Equity-109.29% Return on Assets-45.34% Debt Debt-to-Equity Ratio0.02 Current Ratio17.35 Quick Ratio17.35 Sales & Book Value Annual Sales$2.96 million Price / Sales358.63 Cash FlowN/A Price / Cash FlowN/A Book Value$2.48 per share Price / Book15.04Miscellaneous Outstanding Shares28,460,000Free Float27,189,000Market Cap$1.06 billion OptionableNot Optionable Beta0.99 Key ExecutivesJonathan ViolinPresident, Chief Executive Officer & DirectorCarrie MelvinChief Operating OfficerKristian Franz HumerChief Financial, Accounting & Business OfficerVahe BedianChief ScientistBarrett KatzChief Medical OfficerKey CompetitorsFulgent GeneticsNASDAQ:FLGTRadNetNASDAQ:RDNTCareDxNASDAQ:CDNAProgenityNASDAQ:PROGCastle BiosciencesNASDAQ:CSTLView All CompetitorsInsiders & InstitutionsNew York State Common Retirement FundBought 4,804 shares on 1/30/2023Ownership: 0.080%Moody Aldrich Partners LLCBought 58,911 shares on 1/24/2023Ownership: 0.207%Lara MeisnerSold 6,843 sharesTotal: $244,021.38 ($35.66/share)Barrett KatzSold 24,853 sharesTotal: $924,780.13 ($37.21/share)Barrett KatzSold 4,147 sharesTotal: $153,480.47 ($37.01/share)View All Insider TransactionsView All Institutional Transactions VRDN Stock - Frequently Asked Questions Should I buy or sell Viridian Therapeutics stock right now? 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Viridian Therapeutics in the last year. There are currently 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VRDN shares. View VRDN analyst ratings or view top-rated stocks. What is Viridian Therapeutics' stock price forecast for 2023? 9 equities research analysts have issued 1-year target prices for Viridian Therapeutics' shares. Their VRDN share price forecasts range from $35.00 to $51.00. On average, they predict the company's share price to reach $44.60 in the next twelve months. This suggests a possible upside of 19.6% from the stock's current price. View analysts price targets for VRDN or view top-rated stocks among Wall Street analysts. How have VRDN shares performed in 2023? Viridian Therapeutics' stock was trading at $29.21 at the beginning of the year. Since then, VRDN shares have increased by 27.7% and is now trading at $37.30. View the best growth stocks for 2023 here. When is Viridian Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 9th 2023. View our VRDN earnings forecast. How were Viridian Therapeutics' earnings last quarter? Viridian Therapeutics, Inc. (NASDAQ:VRDN) released its quarterly earnings data on Monday, November, 14th. The company reported ($0.86) earnings per share for the quarter, topping the consensus estimate of ($0.87) by $0.01. The business had revenue of $1.20 million for the quarter, compared to analysts' expectations of $0.52 million. Viridian Therapeutics had a negative net margin of 6,009.30% and a negative trailing twelve-month return on equity of 109.29%. What is Viridian Therapeutics' stock symbol? Viridian Therapeutics trades on the NASDAQ under the ticker symbol "VRDN." Who are Viridian Therapeutics' major shareholders? Viridian Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Moody Aldrich Partners LLC (0.21%), New York State Common Retirement Fund (0.08%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Barrett Katz, Fairmount Funds Management Llc, Jonathan Violin, Lara Meisner and Life Sciences Public F Frazier. View institutional ownership trends. How do I buy shares of Viridian Therapeutics? Shares of VRDN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Viridian Therapeutics' stock price today? One share of VRDN stock can currently be purchased for approximately $37.30. How much money does Viridian Therapeutics make? Viridian Therapeutics (NASDAQ:VRDN) has a market capitalization of $1.06 billion and generates $2.96 million in revenue each year. The company earns $-79,410,000.00 in net income (profit) each year or ($4.22) on an earnings per share basis. How can I contact Viridian Therapeutics? Viridian Therapeutics' mailing address is 6200 LOOKOUT ROAD, BOULDER CO, 80301. The official website for the company is www.viridiantherapeutics.com. The company can be reached via phone at (617) 272-4600, via email at daniel@lifesciadvisors.com, or via fax at 760-537-4101. This page (NASDAQ:VRDN) was last updated on 2/2/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.